# Phase 2 leukemia trials recruiting: 314 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 314 trials in phase 2 for leukemia that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 leukemia trials: 314 rows for $15.70, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 5 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/leukemia

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 314
- Recruiting or not yet: 314
- Read on: November 19, 2026

## Trials

The 25 newest of 314, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 13, 2026 | NCT07937124 | An All-Oral Combination of Ivosidenib, Sonrotoclax, and Chidamide for Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation (ISC) | First Affiliated Hospital of Zhejiang University | Phase 2 | Not yet recruiting | Acute Myeloid Leukemia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937124) |
| November 9, 2026 | NCT07925554 | Interferon-α Maintenance in Favorable-Risk AML | Peking University People's Hospital | Phase 2 | Recruiting | AML (Acute Myeloid Leukemia) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925554) |
| October 27, 2026 | NCT07899398 | A Trial to Evaluate the Efficacy and Safety of a Fitness-adapted Thera-py Approach With Either Continuous Zanubrutinib Monotherapy or... | German CLL Study Group | Phase 2 | Not yet recruiting | CLL (Chronic Lymphocytic Leukemia) | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899398) |
| October 21, 2026 | NCT07887061 | Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic... | Fred Hutchinson Cancer Center | Phase 2 | Not yet recruiting | Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887061) |
| October 15, 2026 | NCT07874737 | Mitoxantrone Hydrochloride Liposome Combined With Cladribine And Sotorasib For Relapsed Refractory Acute Myeloid Leukemia | The Affiliated People's Hospital of Ningbo University | Phase 2 | Not yet recruiting | Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874737) |
| October 9, 2026 | NCT07867626 | Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AML | Rutgers, The State University of New Jersey | Phase 2 | Not yet recruiting | Acute Myeloid Leukaemia (AML) | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07867626) |
| October 7, 2026 | NCT07862517 | Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of... | National Cancer Institute (NCI) | Phase 2 | Not yet recruiting | Acute Myeloid Leukemia | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862517) |
| September 14, 2026 | NCT07819396 | Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic... | Fred Hutchinson Cancer Center | Phase 2 | Not yet recruiting | Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute... | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07819396) |
| September 14, 2026 | NCT07819214 | Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI | University of California, Irvine | Phase 2 | Not yet recruiting | CLL, CLL (Chronic Lymphocytic Leukemia), Chronic Lymphocytic Leukemia (CLL), BTKi | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07819214) |
| September 10, 2026 | NCT07812246 | Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial | City of Hope Medical Center | Phase 2 | Not yet recruiting | Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07812246) |
| September 4, 2026 | NCT07804901 | Asciminib Frontline Risk Adapted | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Chronic Myeloid Leukemia (CML) | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07804901) |
| September 1, 2026 | NCT07796373 | Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase... | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | Not yet recruiting | Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796373) |
| August 27, 2026 | NCT07789574 | Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations | Sponsor not shown (see the record) | Phase 2 | Recruiting | Chronic Myeloid Leukemia (CML) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07789574) |
| August 24, 2026 | NCT07783100 | Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia | The First Affiliated Hospital of Xiamen University | Phase 2 | Recruiting | Relapsed or Refractory Acute Myeloid Leukemia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783100) |
| August 10, 2026 | NCT07755202 | Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Acute Myeloid Leukemia, AML With FLT3 Mutation | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07755202) |
| August 10, 2026 | NCT07754799 | A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Acute Myeloid Leukemia (AML) | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07754799) |
| August 5, 2026 | NCT07748455 | HMA-Venetoclax Induction in Newly Diagnosed AML | Pakistan Blood and Marrow Transplant (PBMT) Group | Phase 2 | Not yet recruiting | AML, AML (Acute Myeloid Leukemia) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748455) |
| August 3, 2026 | NCT07743112 | A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia | Maxinovel Pty., Ltd. | Phase 2 | Recruiting | Acute Myeloid Leukemia | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743112) |
| July 31, 2026 | NCT07739459 | Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) | The Lymphoma Academic Research Organisation | Phase 2 | Not yet recruiting | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 95 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07739459) |
| July 31, 2026 | NCT07738887 | Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations | The Lymphoma Academic Research Organisation | Phase 2 | Not yet recruiting | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07738887) |
| July 29, 2026 | NCT07735208 | Geriatric Assessment-Guided Treatment Selection in Older Adults With Acute Myeloid Leukemia | University of Rochester | Phase 2 | Not yet recruiting | Acute Myeloid Leukemia | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07735208) |
| July 29, 2026 | NCT07734038 | Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | Sponsor not shown (see the record) | Phase 2 | Recruiting | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07734038) |
| July 17, 2026 | NCT07710534 | Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN | Virginia Commonwealth University | Phase 2 | Recruiting | Relapsed / Refractory AML, High Risk Myelodysplastic Syndrome, High Risk Myeloproliferative Neoplasms | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07710534) |
| July 16, 2026 | NCT07709000 | A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) | Merck Sharp & Dohme LLC | Phase 2 | Recruiting | Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Hematologic Malignancies | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07709000) |
| July 13, 2026 | NCT07698080 | Dexamethasone, Intravenous Injection of Human Immunoglobulin, and Increased Infusion of Mononuclear Cells to Reduce Donor Specific... | Hematology department of the 920th hospital | Phase 2 | Not yet recruiting | Leukemia, Lymphoma, Thalassemia, Aplastic Anemia, Myelodysplastic Syndromes | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07698080) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| M.D. Anderson Cancer Center | 28 |
| National Cancer Institute (NCI) | 15 |
| Institute of Hematology & Blood Diseases Hospital, China | 15 |
| The First Affiliated Hospital of Soochow University | 10 |
| Fred Hutchinson Cancer Center | 9 |
| City of Hope Medical Center | 7 |
| First Affiliated Hospital of Zhejiang University | 7 |
| Memorial Sloan Kettering Cancer Center | 6 |
| Ruijin Hospital | 6 |
| Peking University People's Hospital | 4 |
| Masonic Cancer Center, University of Minnesota | 4 |
| Beijing 302 Hospital | 4 |
| University of Utah | 4 |
| The First Affiliated Hospital of Xiamen University | 4 |
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 3 |
| Chinese PLA General Hospital | 3 |
| Gruppo Italiano Malattie EMatologiche dell'Adulto | 3 |
| Massachusetts General Hospital | 3 |
| Technische Universität Dresden | 3 |
| Medical College of Wisconsin | 3 |
| Navy General Hospital, Beijing | 2 |
| Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 2 |
| The Lymphoma Academic Research Organisation | 2 |
| Washington University School of Medicine | 2 |
| Hematology department of the 920th hospital | 2 |

## By country

| Country | Trials |
| --- | --- |
| United States | 155 |
| China | 79 |
| France | 18 |
| Italy | 16 |
| Spain | 15 |
| Germany | 13 |
| Canada | 12 |
| United Kingdom | 9 |
| Brazil | 8 |
| Puerto Rico | 8 |
| Australia | 7 |
| Poland | 7 |
| Belgium | 6 |
| South Korea | 6 |
| Denmark | 6 |
| Israel | 5 |
| Netherlands | 5 |
| Czechia | 5 |
| Austria | 4 |
| Switzerland | 4 |
| Sweden | 4 |
| Romania | 3 |
| Norway | 3 |
| Hungary | 3 |
| Russia | 3 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Interior design firms in the United States](https://specstream.ai/data/businesses/interior-design-firms/united-states)
- [Tableware suppliers in the United States](https://specstream.ai/data/businesses/tableware-suppliers/united-states)
- [Court reporters in the United States](https://specstream.ai/data/businesses/court-reporters/united-states)
- [Mortgage lenders in the United States](https://specstream.ai/data/businesses/mortgage-lenders/united-states)
- [Workers compensation law firms in the United States](https://specstream.ai/data/businesses/workers-compensation-law-firms/united-states)
- [Fence contractors in the United States](https://specstream.ai/data/businesses/fence-contractors/united-states)
